Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1983-12-01
1987-04-07
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514648, A61K 3140, A61K 31135
Patent
active
046561870
ABSTRACT:
Mammary cancers are inhibited by administration of a combination of two drugs. The first compound is 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-pyrrolidinoethoxy)benzoyl]benzo[b]th iophene, and the second compound is tamoxifen.
REFERENCES:
patent: 2914563 (1959-11-01), Allen et al.
patent: 3272841 (1966-09-01), DeWald
patent: 3274213 (1966-09-01), Lednicer
patent: 3875242 (1975-04-01), Lednicer
patent: 4133814 (1979-01-01), Jones et al.
patent: 4230862 (1980-10-01), Suarez et al.
Faye et al., Biochem. And Biophys. Res. Comm. 93, 1225-31 (1980).
Sutherland et al., Nature 288, 273-75 (1980).
U.S. Application Ser. No. 246,335, Jones, Eli Lilly and Co. filed Apr. 3, 1981.
Black Larry J.
Clemens James A.
Barclay Bruce J.
Eli Lilly and Company
Goldberg Jerome D.
Jones Joseph A.
Whitaker Leroy
LandOfFree
Treatment of mammary cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of mammary cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of mammary cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1087124